These data suggest that GILT expression in melanoma cells does not alter surface or intracellular HLA class II protein levels, but that a very marginal increase in Ii or HLA-DM may be detected in tumors expressing high levels of GILT. This evidence concerns the gene IFI30 and melanoma.